Lupin Limited — Updates, 30-12-2024: Press Release

Lupin Limited has acquired the Huminsulin® product range from Eli Lilly to strengthen its diabetes portfolio in India. The Huminsulin lineup includes Insulin Human products like Huminsulin R, NPH, and blends for managing type 1 and type 2 diabetes, addressing the treatment needs of a significant diabetic population in the country. This strategic acquisition highlights Lupin's commitment to providing high-quality and affordable healthcare solutions.

Nilesh Gupta, Managing Director, emphasized that the move aligns with Lupin's ongoing mission to combat diabetes and offer comprehensive care. Rajeev Sibal, President of India Region Formulations, noted that this acquisition is pivotal for expanding their offerings and helping millions lead healthier lives. The deal positions Lupin as a key player in the diabetes treatment landscape, showcasing potential growth in an increasingly vital therapeutic area.